CoChat

Recent Advances in Our Knowledge of mCRC Tumor Biology and Genetics: A Focus on Targeted Therapy Development

Open access
Gmeiner, William H · 2021 · OncoTargets and Therapy

The DOI matches its Crossref record; 91 of the 91 references it cites were found in a registry or an index.

Abstract

Metastatic colorectal cancer (mCRC) remains a highly lethal malignancy although considerable progress has resulted from characterizing molecular alterations such as RAS mutation status and extent of microsatellite instability (MSI) to guide optimal use of available therapies. The availability of gene expression profiling, next generation sequencing technologies, proteomics analysis and other technologies provides high resolution information on individual tumors, including metastatic lesions to better define intra-tumor and inter-tumor heterogeneity. Recent literature applying this information to further customize personalized therapies is reviewed. Current biomarker-based stratification used to select optimal therapy that is personalized to the mutation profile of individual tumors is described. Recent literature using whole exome sequencing of metastatic lesions and primary CRC tumors and other advanced technologies to more fully elucidate the tumor biology specific to mCRC sub-types and to develop more precise therapies that improve outcomes is also reviewed. Keywords: colorectal cancer, metastasis, mutation, whole exome sequencing, targeted therapy

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2147/ott.s242224

Cites

91 of 91 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Summary of biomarker-based stratification to identify optimal front-line treatment for mCRC patients. Screening for KRAS/NRAS and BRAF activating mutations and for high MSI and deficiencies in MMR is recommended by the NCCN prior to treatment. %-positive indicates percent of patients that test positive for the biomarker indicated.
Figure 1 Summary of biomarker-based stratification to identify optimal front-line treatment for mCRC patients. Screening for KRAS/NRAS and BRAF activating mutations and for high MSI and deficiencies in MMR is recommended by the NCCN prior to treatment. %-positive indicates percent of patients that test positive for the biomarker indicated.CC BY-NC · PubMed Central
Figure 2 Summary of mutations in the Wnt/β-catenin, RAS/RAF/MAPK, TGF-β, and TP53 pathways that occur during the course of CRC tumor progression from normal epithelium to adenoma to carcinoma and to metastasis are listed. Mutations in light blue were reported by Ishaque et al10, light yellow from Yaeger et al11 and light green from Li et al76. Specific metastasis-specific alterations identified in each study are highlighted and potential new therapies for mCRC are indicated.
Figure 2 Summary of mutations in the Wnt/β-catenin, RAS/RAF/MAPK, TGF-β, and TP53 pathways that occur during the course of CRC tumor progression from normal epithelium to adenoma to carcinoma and to metastasis are listed. Mutations in light blue were reported by Ishaque et al10, light yellow from Yaeger et al11 and light green from Li et al76. Specific metastasis-specific alterations identified in each study are highlighted and potential new therapies for mCRC are indicated.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 91 references

Research works printed but not linked: 2

  1. Gustavson, 2008, Arch Pathol Lab Med, 132, 1746, 10.1043/1543-2165-132.11.1746 · doi:10.1043/1543-2165-132.11.1746
  2. Salonga, 2000, Clin Cancer Res, 6, 1322

Cited by

Metadata

Authors
Gmeiner, W. H.
Affiliations
Wake Forest University Health Sciences (US)
Corresponding author
Gmeiner, William H
Venue
OncoTargets and Therapy
Published
2021-03
Volume
Volume 14
Pages
2121-2130
ISSN
1178-6930 (ISSN-L)
OpenAlex
W3139459873
Cited by
18
References
91
Citations by year
2026: 1 · 2025: 3 · 2024: 4 · 2023: 2 · 2022: 6 · 2021: 2
FWCI
0.42
Type
journal article
Language
en
Open access
Locations
  • OncoTargets and Therapy (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by-nc)
Funders
  • Comprehensive Cancer Center at Wake Forest Baptist Medical Center (P30CA012197)
  • National Institutes of Health (CA012197)
  • National Cancer Institute (R21CA218933, P30CA012197)
Topics
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
  • Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
Keywords
metastatic colorectal cancer, tumor biology, RAS mutations, microsatellite instability, intratumoral heterogeneity, intertumoral heterogeneity, personalized treatment, targeted therapy, exome sequencing, metastasis, molecular subtypes

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.